GLUE

Monte Rosa Therapeutics Inc

Add to Watchlist

Advanced Chart

14.320

0(0.000%)1D

Line

Candle

YTD

High

14.390

Open

14.190

VWAP

14.29

Vol

193.46K

Mkt Cap

932.49M

Low

14.150

Amount

2.76M

EV/EBITDA(TTM)

32.14

Total Shares

61.15M

541.23M

EV/OCF(TTM)

3.63

P/S(TTM)

6.50

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

6.10M

-73.7%

-0.480

+220%

6.10M

-92.82%

-0.465

-181.58%

17.09M

-71.82%

-0.312

-215.63%

Estimates Revision

The market is revising Upward the revenue expectations for Monte Rosa Therapeutics, Inc. (GLUE) for FY2025, with the revenue forecasts being adjusted by 5.82% over the past three months. During the same period, the stock price has changed by 229.20%.

Revenue Estimates for FY2025

Revise Upward

+5.82%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-72.88%

In Past 3 Month

Stock Price

Go Up

+229.20%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 14.320

Low

16.00

Averages

16.00

High

16.00

Current: 14.320

Low

16.00

Averages

16.00

High

16.00

Wedbush

Robert Driscoll

Buy

Maintains

$15 → $17

2025-03-21

Reason

Wedbush

Robert Driscoll

Price Target

$15 → $17

2025-03-21

Maintains

Buy

Reason

Wedbush raised the firm's price target on Monte Rosa Therapeutics to $17 from $15 and keeps an Outperform rating on the shares after the company reported Q4 financials and provided clinical updates for its VAV1 and MRT-2359 programs in immunology and oncology, respectively. Monte Rosa shared healthy volunteer data for its MRT-6160 VAV1 degrader program showing a favorable safety profile, along with deep VAV1 degradation of over 90% and substantial ablation of T and B cell function shown by reduction in cytokine release from T and B cells following ex vivo stimulation, the firm notes. Taken together, Wedbush sees these data as providing robust support for further evaluation of the molecule in Phase 2 studies in immune mediated diseases, including autoimmune indications such as colitis and rheumatoid arthritis.

Wells Fargo

Derek Archila

Hold

Maintains

$11 → $10

2025-03-21

Reason

Wells Fargo

Derek Archila

Price Target

$11 → $10

2025-03-21

Maintains

Hold

Reason

Wells Fargo analyst Derek Archila lowered the firm's price target on Monte Rosa Therapeutics to $10 from $11 and keeps an Equal Weight rating on the shares. The firm likes the progress on MRT-6160 and believes it increases the odds of future milestones and royalties. That said, Monte Rosa Therapeutics' programs remain early and with limited catalysts in the near term, Wells expects shares to be range bound.

Wells Fargo

Derek Archila

Buy

Hold

Downgrades

$14 → $11

2024-12-19

Reason

Wells Fargo

Derek Archila

Price Target

$14 → $11

2024-12-19

Downgrades

Buy

Hold

Reason

Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock's upside is limited in 2025 given MRT-6160 is now partnered and the MRT-2359 Phase 1 update in Q1 may have too few patients to fully interpret its profile. As such, Monte Rosa shares are likely to be range bound in 2025, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Monte Rosa Therapeutics Inc (GLUE.O) is -8.34, compared to its 5-year average forward P/E of -4.67. For a more detailed relative valuation and DCF analysis to assess Monte Rosa Therapeutics Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.67

Current PE

-8.34

Overvalued PE

-1.19

Undervalued PE

-8.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.37

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.44

Undervalued EV/EBITDA

-6.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.43

Current PS

14.32

Overvalued PS

22.09

Undervalued PS

-3.23

Financials

Annual

Quarterly

FY2025Q3

YoY :

+38.54%

12.77M

Total Revenue

FY2025Q3

YoY :

+24.31%

-32.98M

Operating Profit

FY2025Q3

YoY :

+13.50%

-27.08M

Net Income after Tax

FY2025Q3

YoY :

+13.79%

-0.33

EPS - Diluted

FY2025Q3

YoY :

-566.40%

99.78M

Free Cash Flow

FY2025Q3

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q3

79.89

FCF Margin - %

FY2025Q3

YoY :

-18.07%

-212.10

Net Margin - %

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

58.4K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

3.1M

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.8M

Volume

Months

6-9

3.2M

Volume

Months

0-12

2.8M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

58.4K

USD

Months

0-12

0.0

USD

Months

GLUE News & Events

Events Timeline

2025-11-09 (ET)

2025-11-09

13:15:09

Monte Rosa Therapeutics unveils preclinical findings on MRT-8102

2025-11-06 (ET)

2025-11-06

07:03:26

Monte Rosa Therapeutics projects funding to last until 2028

2025-11-06

07:03:04

Monte Rosa Therapeutics Announces Q3 Revenue of $12.8M, Exceeding Consensus Estimate of $7.37M

News

9.0

11-08Newsfilter

Monte Rosa Therapeutics Unveils Preclinical Findings on MRT-8102, a NEK7-targeted Molecular Glue Degrader, for Treating Cardiovascular and Cardiometabolic Conditions at AHA Scientific Sessions 2025

9.0

10-01TipRanks

Novartis Shares Surge Following U.S. Approval of Pill for Persistent Skin Flare-Ups

2.0

09-16Benzinga

Dave & Buster's Entertainment Reports Disappointing Results, Alongside Adtran Holdings and Other Major Stocks Declining in Tuesday's Pre-Market Trading